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was carried out after IERB approval. Total of 120/157 patients 30 each, 56-58 yrs old,
with diagnosis of knee OA, Grade – II / III were randomized to receive total dose of
– placebo 800 mg, NRINF02 (Curcuma longa linn.-standardized extract) 500 mg and
GS 1500 mg and their combination orally, for 42 days with follow-up on 21st and
42nd day. Primary efficacy outcomes were measured using WOMAC, Visual Ana-
logue Scale [VAS], Clinician Global Impression of Change [CGIC] and clinical-exam-
ination and secondary efficacy outcome by recording number of paracetamol tab-
lets as rescue medication. Safety profile was monitored at each clinic visit by
recording adverse reactions. Chi-square test, repeated measures ANOVA and
mixedmodel analysis were performed using SPSS 16.0 and presented as inferential
statistics. RESULTS: Patients on NRINF02 showed significant decrease in -WOMAC
 p  0.05, VAS  p  0.05, CGIC  p  0.001, used lesser number of rescue
medications(p  0.05) and demonstrated greater clinical and subjective improve-
ment compared to placebo group. All study medications demonstrated acceptable
safety profile. CONCLUSIONS: Study patients exhibited acceptable tolerability and
efficacy profile with NRINF02 when assessed using algofunctional indices for OA.
NRINF02 may therefore be considered as an alternative treatment option in pa-
tients intolerant to NSAIDs presenting with uncomplicated knee OA.
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OBJECTIVES: To conduct a systematic review to estimate the disease burden of
Rheumatoid Arthritis in Mainland China. METHODS: Publications between 1990
and 2010 were systematically searched from 10 electronic databases. Observa-
tional studies consisting of disease burden of Rheumatoid Arthritis were included.
Data were extracted using a standardized form. Quality of searched publications
was evaluated by the quality rating scale. Meta –analysis of prevalence rates was
conducted using the generic inverse variancemodel.Meta-analysis of SF-36 quality
of life scores were performed to assess 8 dimensions by RevMan5.0 software, with
weightedmean difference (WMD) used as the indicator of intervention effect. Sen-
sitivity analyses were performed to evaluate the impact of different research
qualities. RESULTS: In total, 20 studies were included, which general quality was
evaluated asmoderate. The weighted prevalence was 0.42%(95%CIxF0.39%-0.45%).
The weighted prevalence in females was significantly higher than that in males.
But therewas no statistically significant difference on different periods, or between
the southern and northern sections of Mainland China. Themeta-analysis showed
that there was a statistically significant difference between WMD of the 8 dimen-
sions of the SF-36. Sensitivity analysis showed that the weighted results were
stable. The incidence rate of RA was 14.7/100 000. In some studies, it is estimated
that there was 4.92 healthy life year per patient lost in his life resulting from RA.
CONCLUSIONS: The prevalence of RA in Mainland China is similar to that of west-
ern countries. Considering the high disability risk of RA, additional economics
burden studies, especially indirect burden studies, will be helpful for enhance the
awareness of RA and to provide patients treatment options and support.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic, autoimmune inflammatory
disease imposing a great burden on individuals and society, highlight by the intro-
duction of new expensive biologics within this decade. This study compared the
trend of health care expenditures and biologics costs due to rheumatoid arthritis
from 1999-2009.METHODS: This studywas based on data from theNational Health
Insurance Research Database (NHIRD) released by the National Health Research
Institute, which representing 99% of the entire population of Taiwan.We identified
all patients by both with a primary diagnosed code ICD-9-CM 714.0 and with RA
Catastrophic Illness certificate. Patients who fulfilled the American College of
Rheumatology criteria for the classification of RA are qualified to register in Cata-
strophic Illness file and can benefit for waiving the outpatient registration fee. The
indication for reimbursement the biologics were DAS28xa5.1 for two continuous
measures 1 month apart in Taiwan. RESULTS: After adjusting by using WHO 2000
population, we found the incidence rate of RA is stable around 0.01% from 1999 to
2009 in Taiwan. However the prevalence rate is increasing from0.07% to 1.13%. The
average annual growth rates of total medication cost for RA patients (51.6%) are
higher than the growth rates of total treatment cost for RA patient (36.7%) during
the study period from 1999 to 2009. In addition, Outpatient drug cost growth rates
(11.5%-44.1%) were much higher than that of inpatient drug growth rates (2.4%-
26.7%) during this period. Enbrel was reimbursed by the National Health Insurance
since 2003 and next year it reflected an 11.6% growth rate in expenditure. Although
there are three biologics reimbursed by NHI for qualified RA patients, Enbrel dom-
inates on the market. CONCLUSIONS: The introduction of biologics may benefit to
the decreasing rate of inpatient admission and costs.
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OBJECTIVES: To examine the mortality and medical cost during the first and sec-
ond year following fractures among elder women by different age groups.
METHODS: Using the inpatient and outpatient database of National Health Insur-
ance to define new hip fracture (ICD9 code 820, 733.14), vertebral fracture (ICD9
code 805, 806, 733.13), wrist fracture (ICD9 code 813, 733.12) and other fracture (ICD9
code 807, 808, 810, 811, 812, 821, 823, 733.10, 733.11, 733.15, 733.16, 733.19) cases
from 2006 to 2009. We divided age into ten groups between 50-100 years. The HR of
mortality and the incremental costs compared to the population without any frac-
ture history in each group were estimated by cox proportional survival model and
generalized linear model. RESULTS: The HR of mortality after hip fracture in each
group ranged from 19.67 to 1.43 while after vertebral fracture ranged from 5.60 to
1.11. The extra costs (in NTD) of hip fracture during first year in each group were
NT$178 535, NT$158 831, NT$184 334, NT$190 206, NT$179 261, NT$160 565, NT$136
195, NT$136 194, NT$110 476, NT$41 194. In the second year, the extra costs of hip
and clinical vertebral fracture were NT$221 036 and NT$135 912, respectively.
CONCLUSIONS: Hip and vertebral fractures result in significant mortality and
costs. These results indicate potential benefits from interventions aimed at reduc-
ing fracture incidences.
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OBJECTIVES: Rheumatoid arthritis (RA) is associated with poor quality of life and
higher health care cost. This study aimed to assess the hospitalization costs of
rheumatoid arthritis (RA) and to characterize predictors of these costs.METHODS:
A total of 676 RA patients were randomly selected by stratified two-stage sampling
from the China Basic Health Insurance database in 2009 and 2008. All information
of patient demographic characters, clinical and costs were collected for the analy-
sis. We used generalized estimating equations to examine potential predictors of
the costs. RESULTS: Among 676 RA patients (mean age 57.8 years; 75.2% female),
Themean hospital length-of-stay was 19.4 days for RA patients with basic medical
insurance for urban employees and 15.0 days for those patients with basic medical
insurance for urban residents. The average inpatient cost was Chinese Yuan (CNY)
8521.5 (median:xx6608.7, IQR:xx4223.5-xx10383.3), higher than those without
RA(CNY7670) and the average drug cost accounts for 49.95%of the total cost (mean:
xx5295.3). Themultiple linear regressions showed that the hospital cost of patients
with basic medical insurance for urban employees had 39.6% higher costs than
those with basic medical insurance for urban residents(P0.001). Patients from
tertiary hospitals had 97.8% higher costs than those from primary hospitals; (P 
0.001) and patients from municipalities had 46.0% higher costs than those from
county-level cities( P  0.01). CONCLUSIONS: Patients with RA is associated with
high hospitalization costs. Costs are now driven predominantly by the cost of
drugs, primarily biologic agents. and sociodemographic characteristics such as
types of health insurance and levels of hospitals also play an important role in
determination of costs.
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OBJECTIVES: Ankylosing spondylitis (AS) is associated with poor quality of life and
higher health care cost. This study aimed to assess the inpatient costs of AS and to
characterize predictors of these costs. METHODS: A total of 560 AS patients were
randomly selected by stratified two-stage sampling from the China Basic Health
Insurance database in 2009. All information of patient demographic characters,
clinical and costs were collected for the analysis. We used generalized estimating
equations to examine potential predictors of the costs. RESULTS: Among 560 AS
patients (mean age 55.7 years;57% female), Themeanhospital length-of-staywas
15.2 days for AS patients with basicmedical insurance for urban employees and 9.8
days for those with basic medical insurance for urban residents(P0.001). The
average inpatient cost was RMB 8173.3 yuan (median:4368.7, IQR:2836.1-7399.7)
and the average medical service cost accounts for 68.0% of the total cost (mean:
5560.5; median:2376.0, IQR:1395.0-3882.7). The multiple linear regressions showed
that the patients from tertiary hospitals had 84.7% higher costs than those from
primary hospitals (P  0.001) , patients from the east area have 30.7% higher costs
than those from the west area ( P  0.01), and patients from municipalities had
72.5% higher costs than those from county-level cities( P  0.05). CONCLUSIONS:
Patients with AS is associated with high hospital costs. Costs are now driven pre-
dominantly by the cost of medical service, and sociodemographic characteristics
such as regions and levels of hospitals also play an important role in determination
of costs.
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